Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder

Trial Profile

An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Vibegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPOWUR
  • Sponsors Urovant Sciences
  • Most Recent Events

    • 08 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 28 Aug 2018 According to an Urovant Sciences media release, he company expects to report top-line results in 2019.
    • 28 Mar 2018 Status changed from planning to recruiting, according to an Urovant Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top